Overview

PH-797804 Versus Placebo For The Treatment Of Neuropathic Pain Associated With Post-Herpetic Neuralgia

Status:
Completed
Trial end date:
2008-12-01
Target enrollment:
Participant gender:
Summary
This is a proof-of-concept study to determine if PH-797804 reduces neuropathic pain associated with post-herpetic neuralgia. Suitable patients will be randomized to receive either PH-797804 or placebo for 4 weeks, during which time they will also record their pain symptoms using various pain scales.
Phase:
Phase 2
Details
Lead Sponsor:
Pfizer